'Buy' Sun Pharma Maintains Systematix, Sees Checkpoint Acquisition To Strengthen Onco Derma Portfolio

Systematix retains estimates on Sun Pharma and retain Buy with a target price of Rs 2,206 based on 35 times FY27E earnings per share.